Tirzepatide – 30mg
Original price was: $280.00.$170.00Current price is: $170.00.
Tirzepatide is a synthetic research peptide acting as a dual agonist of GIP and GLP-1 receptors, two incretin pathways extensively studied in metabolic regulation.
Frequently used in research on insulin signaling, glucagon suppression, and gastrointestinal motility, it remains a key compound in endocrine and metabolic science.
DUAL-ACTION PEPTIDE
Two Receptors, One Molecule: The Power of Dual Activation
Tirzepatide works differently from other metabolic peptides. Instead of targeting just one receptor, it activates two key receptors at once: GLP-1 and GIP. Think of it like having two keys that open two different locks simultaneously. This dual approach has been extensively documented in published research for its effects on how the body handles glucose, stores energy, and regulates appetite.
- Activates both GLP-1 and GIP receptors together
- First compound designed with this dual mechanism
- One injection per week (long-lasting effects)
- Well-documented in peer-reviewed scientific journals
- Stable compound suitable for research protocols
For laboratory research use only. Not for human consumption.
SMART DESIGN
Why Two Receptors Work Better Than One
Tirzepatide wasn’t designed to activate both receptors equally. It binds strongly to GIP receptors (like the natural hormone) but more gently to GLP-1 receptors. This “unbalanced” design isn’t a flaw — it’s intentional. Research shows this combination creates a synergistic effect, meaning the two receptors working together produce better results than either one alone.
- Strong binding to GIP receptors (equal to natural hormone)
- Gentler binding to GLP-1 receptors (~5× less than natural)
- This balance creates synergy between both pathways
- Combined effect greater than single-receptor activation
- Opens new possibilities for metabolic research
For laboratory research use only. Not for human consumption.
RESEARCH APPLICATIONS
What Researchers Are Studying with Tirzepatide
Tirzepatide has become a valuable tool for scientists exploring how the body manages energy and metabolism. Because it affects two pathways at once, researchers can study questions that were difficult to answer before: How do these systems interact? What happens when both are activated together? The scientific literature continues to expand with new findings.
- Blood sugar regulation and insulin response
- How the body stores and uses energy
- Appetite signals and feeling of fullness
- Liver fat metabolism
- Heart and cardiovascular markers
- Comparing single vs dual receptor effects
For laboratory research use only. Not for human consumption.
Understanding Tirzepatide: The Science Made Simple
Tirzepatide represents a new approach in metabolic research. Most peptides in this category target a single receptor — like GLP-1 agonists such as semaglutide. Tirzepatide is different: it’s the first compound designed to activate both GLP-1 and GIP receptors at the same time. This dual action is why researchers find it so valuable for studying metabolic pathways.
Here’s the interesting part: the molecule doesn’t treat both receptors the same way. It binds to GIP receptors with full strength (just like the body’s natural GIP hormone), but connects to GLP-1 receptors more gently — about 5 times weaker than the natural GLP-1 hormone. Scientists discovered that this “imbalanced” design actually works better than equal activation of both receptors.
Why does this matter? When both pathways are activated together in this specific way, they create what researchers call a synergistic effect. The combined result is greater than what you’d get from activating each receptor separately. It’s like two musicians playing together creating something better than either could alone.
The compound is administered once weekly in research settings, thanks to its long-lasting stability in the body. For scientists studying metabolism, energy balance, glucose regulation, or appetite mechanisms, tirzepatide offers a unique tool to explore how these interconnected systems work together.
For research use only. Not for human consumption.
SCIENTIFIC LITERATURE
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.
- Frias JP, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist. Lancet. 2018;392(10160):2180-2193.
- Gallwitz B. GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes and obesity. Front Endocrinol. 2022;13:1004044.
- Farzam K, Patel P. Tirzepatide. StatPearls Publishing; 2024.
- Efficacy and safety of once-weekly tirzepatide: Systematic review and meta-analysis. Endocrine. 2024.
CERTIFICATE
A detailed summary of the analytical profile, purity, and molecular integrity of the research-grade peptide compound.
Be the first to review “Tirzepatide – 30mg”
Related products
Fat Loss
Fat Loss
Fat Loss
Fat Loss
Fat Loss
Fat Loss
Fat Loss
Fat Loss
Reviews
There are no reviews yet.